Idalina B Beirâo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9049641/publications.pdf

Version: 2024-02-01

686830 580395 34 661 13 25 citations h-index g-index papers 35 35 35 1025 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	P0739PANEL OF SENSITIVE BIOMARKERS OF THE PRIMARY RESPONSE TO RENAL INJURY FOR AN EARLY DIAGNOSIS OF CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	O
2	P0052EMERGING CONCEPTS IN KIDNEY ATTR AMYLOIDOSIS: CHRONIC ADMINISTRATION OF TAFAMIDIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
3	Demographic, clinical characteristics and cardiovascular disease burden in a Portuguese cohort of older chronic kidney disease patients. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2019, 41, 29-37.	0.4	3
4	Deleterious effect of antiâ€angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donorâ€specific antiâ€HLA antibodies. Nephrology, 2019, 24, 347-356.	0.7	20
5	Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 81-82.	1.4	8
6	End-stage renal failure due to transthyretin amyloidosis after liver transplantation: outcomes in 19 registry cases. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 85-86.	1.4	1
7	The ever-growing understanding of transthyretin amyloidosis nephropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 117-118.	1.4	3
8	Impact on mid-term kidney graft outcomes of pretransplant anti-HLA antibodies detected by solid-phase assays: Do donor-specific antibodies tell the whole story?. Human Immunology, 2017, 78, 526-533.	1.2	11
9	Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation. Transplant International, 2017, 30, 347-359.	0.8	36
10	Biomarkers and Imaging Findings of Anderson–Fabry Disease—What We Know Now. Diseases (Basel,) Tj ETC	2q0 <u>1.0</u> 0 rg	BT /Qverlock 1
11	End-Stage Renal Disease versus Death in a Portuguese Cohort of Elderly Patients: An Approach using Competing Event Analysis. Journal of Investigative Medicine, 2017, 65, 1041-1048.	0.7	4
12	Impact of <i>de novo </i> donor-specific anti-HLA antibodies on grafts outcomes in simultaneous pancreas-kidney transplantation. Transplant International, 2016, 29, 173-183.	0.8	21
13	Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation. Transplant Immunology, 2015, 32, 66-71.	0.6	53
14	Oligomeric TTR V30M aggregates compromise cell viability, erythropoietin gene expression and promoter activity in the human hepatoma cell line Hep3B. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 93-99.	1.4	7
15	Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 31-35.	1.4	32
16	Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 117-122.	1.4	71
17	Posttransplant Allosensitization in Low Immunological Risk Kidney and Kidney-Pancreas Graft Recipients. BioMed Research International, 2014, 2014, 1-8.	0.9	5
18	Aqueous humor erythropoietin levels in open-angle glaucoma patients with and without TTR V30M familial amyloid polyneuropathy. Molecular Vision, 2014, 20, 970-6.	1.1	8

#	Article	IF	CITATIONS
19	THE USE OF INTRAVITREAL RANIBIZUMAB TO TREAT NEOVASCULAR GLAUCOMA BECAUSE OF RETINAL AMYLOID ANGIOPATHY IN FAMILIAL AMYLOIDOSIS TRANSTHYRETIN V30M RELATED. Retinal Cases and Brief Reports, 2013, 7, 114-116.	0.3	8
20	Topical Cyclosporine for Severe Dry Eye Disease in Liver-Transplanted Portuguese Patients with Familial Amyloidotic Polyneuropathy (ATTRV30M). European Journal of Ophthalmology, 2013, 23, 156-163.	0.7	7
21	Spatial visual contrast sensitivity in liver transplanted Portuguese familial amyloidotic polyneuropathy (ATTR V30M) patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 152-155.	1.4	8
22	Inability of Mutant Transthyretin V30M to Cross the Blood-Eye Barrier. Transplantation, 2012, 94, e54-e56.	0.5	6
23	No ocular involvement in familial amyloidotic polyneuropathy ATTR V30M domino liver recipients. Transplant International, 2012, 25, 646-651.	0.8	9
24	Progressive myoclonus epilepsy with nephropathy C1q due to SCARB2/LIMP-2 deficiency: Clinical report of two siblings. Seizure: the Journal of the British Epilepsy Association, 2011, 20, 738-740.	0.9	26
25	RECURRENCE OF VITREOUS AMYLOIDOSIS AND NEED OF SURGICAL REINTERVENTION IN PORTUGUESE PATIENTS WITH FAMILIAL AMYLOIDOSIS ATTR V30M. Retina, 2011, 31, 1373-1377.	1.0	25
26	Anticipation of presbyopia in Portuguese familial amyloidosis ATTR V30M. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 92-97.	1.4	9
27	Low serum levels of prohepcidin, but not hepcidin-25, are related to anemia in familial amyloidosis TTR V30M. Blood Cells, Molecules, and Diseases, 2008, 41, 175-178.	0.6	6
28	A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome. Human Molecular Genetics, 2008, 17, 2238-2243.	1.4	99
29	Long-term treatment of anemia with recombinant human erythropoietin in familial amyloidosis TTR V30M. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 205-209.	1.4	8
30	Low Erythropoietin Production in Familial Amyloidosis TTR V30M Is Not Related with Renal Congophilic Amyloid Deposition. Nephron Clinical Practice, 2008, 109, c95-c99.	2.3	6
31	Liver transplantation and anemia in familial amyloidosis ATTR V30M. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 33-37.	1.4	8
32	End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2004, 11 , 27-37.	1.4	52
33	Kidney and anemia in familial amyloidosis type I. Kidney International, 2004, 66, 2004-2009.	2.6	23
34	Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrology Dialysis Transplantation, 2003, 18, 532-538.	0.4	54